Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an announcement.
Australian Clinical Labs Ltd has announced an update on its ongoing share buy-back program. As of March 3, 2025, the company has bought back a total of 2,475,483 ordinary fully paid securities, including 200,000 on the previous day. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, focusing on providing pathology services. The company is known for its comprehensive range of diagnostic services, catering to both private and public healthcare sectors in Australia.
YTD Price Performance: -9.88%
Average Trading Volume: 593,524
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$621.8M
Learn more about ACL stock on TipRanks’ Stock Analysis page.